{"protocolSection":{"identificationModule":{"nctId":"NCT01204697","orgStudyIdInfo":{"id":"ML21869"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)","officialTitle":"A Randomized Phase II Trial of Erlotinib or Intermittent Dosing of Erlotinib and Docetaxel in Male Former-smokers With Locally Advanced or Metastatic Squamous NSCLC in Second-line Setting After Failure on Chemotherapy"},"statusModule":{"statusVerifiedDate":"2015-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-11"},"primaryCompletionDateStruct":{"date":"2014-07","type":"ACTUAL"},"completionDateStruct":{"date":"2014-07","type":"ACTUAL"},"studyFirstSubmitDate":"2010-09-16","studyFirstSubmitQcDate":"2010-09-16","studyFirstPostDateStruct":{"date":"2010-09-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-10-15","resultsFirstSubmitQcDate":"2015-10-15","resultsFirstPostDateStruct":{"date":"2015-11-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-10-15","lastUpdatePostDateStruct":{"date":"2015-11-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This randomized parallel group study will assess the efficacy and safety of erlotinib \\[Tarceva\\], as monotherapy or intermittent dosing with docetaxel, in second-line setting in former-smoker male patients with advanced or metastatic squamous non-small cell lung cancer. Patients will be randomized to receive either Tarceva (150 mg/day orally) as monotherapy or 4 cycles of docetaxel (75 mg/m2 intravenously every 3 weeks) plus Tarceva (150 mg/day orally, days 2-16 each cycle) followed by Tarceva monotherapy. Anticipated time on study treatment is until disease progression."},"conditionsModule":{"conditions":["Non-Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":74,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]"]},{"label":"B","type":"EXPERIMENTAL","interventionNames":["Drug: docetaxel","Drug: erlotinib [Tarceva]"]}],"interventions":[{"type":"DRUG","name":"docetaxel","description":"75 mg/m2 intravenously every 3 weeks for 4 cycles","armGroupLabels":["B"]},{"type":"DRUG","name":"erlotinib [Tarceva]","description":"150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter","armGroupLabels":["B"]},{"type":"DRUG","name":"erlotinib [Tarceva]","description":"150 mg/day orally as monotherapy","armGroupLabels":["A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Free From Disease Progression or Death at 6 Months","description":"According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, progressive Disease (PD) is defined as: for Target Lesions - At least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). (Note: the appearance of one or more new lesions is also considered progression). For Non-Target Lesions - Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).","timeFrame":"Month 6"}],"secondaryOutcomes":[{"measure":"Progression-free Survival (PFS)","description":"Progression-free Survival (PFS) was defined as the interval (in days) between the date of randomization and the first documentation of progressive disease or death from any cause. Participants alive and progression-free were considered as censored at the date of the last tumor assessment when the participant was known to be progression-free. Participants without post-baseline tumor assessment, but known to be alive, were censored at the time of randomization. PFS (days) = (Date of Event - Date of Randomization) + 1. PFS was assessed using the Kaplan-Meier method. Detailed definition of PD is provided in Outcome Measure 1.","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months"},{"measure":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the interval (in days) between the date of randomization and death from any cause. Participants alive at the time of the analysis were censored at the date they were last known to be alive. OS was assessed using the Kaplan-Meier method.","timeFrame":"From randomization until death, assessed up to 18 months"},{"measure":"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR)","description":"Best overall response (complete response \\[CR\\]/partial response \\[PR\\]) was defined as the best response recorded from the start of the treatment until disease progression (PD). Best response in this trial was defined as the best response observed at any post-treatment visits. According to RECIST Version 1.1, CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \\[\\<\\] 10 mm). No new lesions. PR was defined as greater than or equal to \\[\\>=\\] 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months"},{"measure":"Percentage of Participants With Disease Control","description":"Disease control was defined as PR, CR, or SD. Participants who did not achieve a CR or PR or SD were counted as non-responders in the analysis of disease control. According to RECIST Version 1.1, SD was defined as not qualifying for CR, PR, and PD. Detailed definitions of CR and PR are provided in Outcome Measure 4.","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months"},{"measure":"Duration of Response (DoR)","description":"Duration of response (DoR) was defined as the interval (in days) from first documentation of a response (CR/PR depending on which occurred first) to the date of the first documentation of disease progression or death from any cause. Participants presenting a response were considered as censored at the date of the last assessment with a documentation of non-progression. DoR (days) = (Date of PD/death - Date of CR/PR) + 1. Assessments were performed according to RECIST Version 1.1. DoR was assessed using the Kaplan-Meier method. Detailed definitions of CR and PR are provided in Outcome Measure 4.","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* male patients, \\>/=18 years of age\n* former smoker (smoked \\>/= 100 cigarettes in his lifetime and quit \\>12 months before enrollment)\n* locally advanced (stage IIIb), metastatic (stage IV) or recurrent squamous non-small cell lung cancer\n* prior platinum-based therapy for advanced NSCLC\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\nExclusion Criteria:\n\n* uncontrolled symptomatic central nervous system (CNS) metastases\n* prior therapy against epidermal growth factor receptor (EGFR)\n* \\>1 prior chemotherapy for advanced/metastatic NSCLC\n* radiotherapy \\<28 days prior to enrollment\n* history of melanoma at any time, or another malignancy in the last 5 years except for carcinoma in situ of the cervix, basal or squamous cell carcinoma of the skin, or surgically cured malignant neoplasias with a disease-free interval of \\>5 years\n* not fully treated eye inflammation or infection, or predisposing conditions","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Lecce","state":"Apulia","zip":"73100","country":"Italy","geoPoint":{"lat":40.35481,"lon":18.17244}},{"city":"San Giovanni Rotondo","state":"Apulia","zip":"71013","country":"Italy","geoPoint":{"lat":41.70643,"lon":15.7277}},{"city":"Avellino","state":"Campania","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"city":"Parma","state":"Emilia-Romagna","zip":"43100","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"city":"Aviano (PN)","state":"Friuli Venezia Giulia","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"city":"Rome","state":"Lazio","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Rome","state":"Lazio","zip":"00157","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Rome","state":"Lazio","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Cremona","state":"Lombardy","zip":"26100","country":"Italy","geoPoint":{"lat":45.13325,"lon":10.02129}},{"city":"Milan","state":"Lombardy","zip":"20142","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"city":"Monza","state":"Lombardy","zip":"20900","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"city":"Pavia","state":"Lombardy","zip":"27100","country":"Italy","geoPoint":{"lat":45.19205,"lon":9.15917}},{"city":"Sondalo","state":"Lombardy","zip":"23039","country":"Italy","geoPoint":{"lat":46.32983,"lon":10.3269}},{"city":"Macerata","state":"The Marches","zip":"62100","country":"Italy","geoPoint":{"lat":43.29789,"lon":13.45293}},{"city":"Lido di Camaiore","state":"Tuscany","zip":"55043","country":"Italy","geoPoint":{"lat":43.90012,"lon":10.2269}},{"city":"Pisa","state":"Tuscany","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"city":"Pontedera","state":"Tuscany","zip":"56025","country":"Italy","geoPoint":{"lat":43.66141,"lon":10.63067}},{"city":"Treviso","state":"Veneto","zip":"31100","country":"Italy","geoPoint":{"lat":45.66673,"lon":12.2416}},{"city":"Vicenza","state":"Veneto","zip":"36100","country":"Italy","geoPoint":{"lat":45.54672,"lon":11.5475}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Erlotinib","description":"Participants received erlotinib (Tarceva) at a dose of 150 milligram per day (mg/day) orally as monotherapy, up to progressive disease (PD), death, or unacceptable toxicity."},{"id":"FG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 milligram per square meter (mg/m\\^2) as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"38"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"37"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"36"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Randomized, but not treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS) included all randomized participants who received at least one dose of study medication. Participants were analyzed according to treatment received.","groups":[{"id":"BG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."},{"id":"BG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"73"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.4","spread":"8.3"},{"groupId":"BG001","value":"65.9","spread":"8.1"},{"groupId":"BG002","value":"67.2","spread":"8.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"72"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Free From Disease Progression or Death at 6 Months","description":"According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, progressive Disease (PD) is defined as: for Target Lesions - At least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). (Note: the appearance of one or more new lesions is also considered progression). For Non-Target Lesions - Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).","populationDescription":"FAS population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 6","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"0.0","upperLimit":"17.4"},{"groupId":"OG001","value":"8.1","lowerLimit":"0.0","upperLimit":"16.9"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Progression-free Survival (PFS) was defined as the interval (in days) between the date of randomization and the first documentation of progressive disease or death from any cause. Participants alive and progression-free were considered as censored at the date of the last tumor assessment when the participant was known to be progression-free. Participants without post-baseline tumor assessment, but known to be alive, were censored at the time of randomization. PFS (days) = (Date of Event - Date of Randomization) + 1. PFS was assessed using the Kaplan-Meier method. Detailed definition of PD is provided in Outcome Measure 1.","populationDescription":"FAS population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","lowerLimit":"2.13","upperLimit":"4.13"},{"groupId":"OG001","value":"2.82","lowerLimit":"2.30","upperLimit":"3.97"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the interval (in days) between the date of randomization and death from any cause. Participants alive at the time of the analysis were censored at the date they were last known to be alive. OS was assessed using the Kaplan-Meier method.","populationDescription":"FAS population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until death, assessed up to 18 months","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.61","lowerLimit":"3.54","upperLimit":"8.69"},{"groupId":"OG001","value":"8.95","lowerLimit":"6.13","upperLimit":"10.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR)","description":"Best overall response (complete response \\[CR\\]/partial response \\[PR\\]) was defined as the best response recorded from the start of the treatment until disease progression (PD). Best response in this trial was defined as the best response observed at any post-treatment visits. According to RECIST Version 1.1, CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \\[\\<\\] 10 mm). No new lesions. PR was defined as greater than or equal to \\[\\>=\\] 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.","populationDescription":"FAS population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"0.0","upperLimit":"8.15"},{"groupId":"OG001","value":"8.1","lowerLimit":"0.0","upperLimit":"16.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control","description":"Disease control was defined as PR, CR, or SD. Participants who did not achieve a CR or PR or SD were counted as non-responders in the analysis of disease control. According to RECIST Version 1.1, SD was defined as not qualifying for CR, PR, and PD. Detailed definitions of CR and PR are provided in Outcome Measure 4.","populationDescription":"FAS population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","lowerLimit":"25.6","upperLimit":"57.8"},{"groupId":"OG001","value":"37.8","lowerLimit":"22.2","upperLimit":"53.5"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"Duration of response (DoR) was defined as the interval (in days) from first documentation of a response (CR/PR depending on which occurred first) to the date of the first documentation of disease progression or death from any cause. Participants presenting a response were considered as censored at the date of the last assessment with a documentation of non-progression. DoR (days) = (Date of PD/death - Date of CR/PR) + 1. Assessments were performed according to RECIST Version 1.1. DoR was assessed using the Kaplan-Meier method. Detailed definitions of CR and PR are provided in Outcome Measure 4.","populationDescription":"FAS population. Here, number of participants analyzed signifies those participants who had a best overall response of CR or PR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until progressive disease or death, assessed up to 18 months","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity."},{"id":"OG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median and corresponding 95% confidence interval were not estimable as the only participant evaluable was censored."},{"groupId":"OG001","value":"8.69","lowerLimit":"1.87","upperLimit":"10.8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 18 months","eventGroups":[{"id":"EG000","title":"Erlotinib","description":"Participants received erlotinib at a dose of 150 mg/day orally as monotherapy, up to PD, death, or unacceptable toxicity.","seriousNumAffected":15,"seriousNumAtRisk":36,"otherNumAffected":32,"otherNumAtRisk":36},{"id":"EG001","title":"Docetaxel and Erlotinib","description":"Participants received docetaxel at a dose of 75 mg/m\\^2 as an intravenous infusion on Day 1 of each 3-week cycle, and erlotinib at a dose of 150 mg/day orally from Day 2 to Day 16 of each 3-week cycle for 4 cycles, administered in absence of PD, death, or unacceptable toxicity. Following the 4 cycles, erlotinib 150 mg/day was administered orally as monotherapy up to PD, death or unacceptable toxicity.","seriousNumAffected":10,"seriousNumAtRisk":37,"otherNumAffected":35,"otherNumAtRisk":37}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":4,"numAtRisk":37}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Gastrointestinal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Device dislocation","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Respiratory acidosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Uncoded","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":1,"numAtRisk":37}]},{"term":"Angiopathy","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":36},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":9,"numAtRisk":37}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":36},{"groupId":"EG001","numAffected":14,"numAtRisk":37}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":5,"numAtRisk":37}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":36},{"groupId":"EG001","numAffected":10,"numAtRisk":37}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":5,"numAtRisk":37}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":36},{"groupId":"EG001","numAffected":6,"numAtRisk":37}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":3,"numAtRisk":37}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Coordination abnormal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":36},{"groupId":"EG001","numAffected":7,"numAtRisk":37}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":36},{"groupId":"EG001","numAffected":0,"numAtRisk":37}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":36},{"groupId":"EG001","numAffected":12,"numAtRisk":37}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":36},{"groupId":"EG001","numAffected":2,"numAtRisk":37}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"},{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}